Pilot Study of RR-HNK in OCD

Part of paid clinical trials in Palo Alto, California.

Sponsor
Carolyn Rodriguez
Study ID
NCT06575075
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Obsessive-Compulsive Disorder

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • RR-HNK/Hydroxynorketamine — DRUG
    (2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine and a glutamate AMPA receptor antagonist.
  • Placebo — DRUG
    Sterile Saline

Study Details

The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.

Key Dates

Start date
Jan 23, 2026
Status verified
Mar 2026
Primary completion
Nov 30, 2028
Completion
Nov 30, 2029

Study Design

Enrollment
45 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 0.25 mg/kg RR-HNK
    OCD patients in this arm will receive 0.25mg/kg of RR-HNK - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.
  • Experimental: 0.5 mg/kg RR-HNK
    OCD patients in this arm will receive 0.5mg/kg of RR-HNK - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.
  • Placebo Comparator: Placebo (Sterile Saline)
    OCD patients in this arm will receive sterile saline - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.

Primary Outcome Measure

Change in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS) [ Time Frame: Baseline (Visit 3) to Week 1 (Visit 8), up to 1 week ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford University School of MedicinePalo AltoCalifornia94305
Daniel Bello, BS

Find similar trials in Palo Alto, CA

By research site
Stanford University School of Medicine· Palo Alto, CA

Related Studies